Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4319182 | 0.92 | ALDH1A1 (0.62) | ALDH1A1HSD17B10LMNASMN1; SMN2HTT | |
| SCHEMBL4319203 | 0.88 | SLC6A7 (0.56) | ALDH1A1HSD17B10LMNASMN1; SMN2HTT | |
| SCHEMBL4314270 | 0.87 | KDM4E (0.56) | ALDH1A1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL4324263 | 0.84 | AKR1C3 (0.49) | ALDH1A1LMNASMN1; SMN2HTTMEN1 | |
| SCHEMBL4419799 | 0.84 | ALDH1A1 (0.48) | ALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL4326491 | 0.82 | MEN1 (0.59) | ALDH1A1MEN1POLBKMT2AKDM4E | |
| SCHEMBL4331069 | 0.82 | SLC6A7 (0.56) | ALDH1A1LMNASMN1; SMN2HTTMEN1 | |
| SCHEMBL4323113 | 0.82 | ALDH1A1 (0.46) | ALDH1A1LMNASMN1; SMN2HTTMEN1 | |
| SCHEMBL4324392 | 0.81 | KDM4E (0.52) | ALDH1A1KDM4E | |
| SCHEMBL4316964 | 0.80 | ALDH1A1 (0.44) | ALDH1A1LMNASMN1; SMN2HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | claimed |
| WO-2009143404-A1 | PIPERAZINE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) NEGATIVE ALLOSTERIC MODULATORS FOR ANXIETY/DEPRESSION | WYETH (US) | 2009-11-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | ALDH1A1 3104/4885HSD17B10 3322/4885LMNA 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.